$VTRS · Viatris Inc
Viatris Inc. entered into a definitive merger agreement on October 8, 2026, to acquire Pacira BioSciences, Inc. for $36.50 per share in cash, representing an aggregate equity value of $1.65 billion. The transaction will be executed via a tender offer followed by a second-step merger under Delaware Section 251(h), requiring no Pacira stockholder vote. Pacira generated approximately $746 million in total revenue and $177 million in adjusted EBITDA over the twelve months ended June 30, 2026.
- Viatris will acquire all outstanding Pacira shares for $36.50 per share in cash, a $1.65B aggregate equity value.
- Pacira generated ~$746M in total revenue and ~$177M in adjusted EBITDA in the twelve months ended June 30, 2026.
- The deal is expected to close by end of 2026 and be immediately accretive to Viatris' financial guidance metrics.
- Funding primarily from excess cash with remainder from short-term borrowings; minimal impact on gross leverage ratio.
- Pacira brings two patent-protected, high-margin U.S. products: EXPAREL and ZILRETTA, plus a Phase 2 gene therapy candidate.
Extended-hours trading shows VTRS at $17.50, up 0.06% from the regular close, suggesting a muted initial reaction to the $1.65B all-cash deal. The modest move is consistent with a disciplined, balance-sheet-friendly acquisition that preserves financial flexibility.
This is Viatris' largest strategic move into innovative, patent-protected medicines, signaling a pivot from its legacy generics base toward higher-margin specialty therapies.
This deal positions Viatris in the non-opioid pain management space, a high-unmet-need therapeutic area. The acquisition adds U.S. commercial infrastructure and R&D capabilities that complement Viatris' existing fast-acting meloxicam opportunity and global generics platform.
The tender offer is conditioned on at least a majority of Pacira shares being tendered and HSR antitrust clearance. Competing offers could emerge. Integration risk exists around realizing expected cost and revenue synergies, and Pacira's products face eventual patent cliffs.
Get filings like this before the market reacts.
Real-time SEC filing alerts, AI summaries, and a free daily digest — plus portfolio tracking that ties filings to your positions.